Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Rui Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9428-941X; OpenAlex author ID A5100448569. Sources: ClinicalTrials.gov.

Their work

Papers
13 (first author 2, last author 3)
Trials
2
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper, 1 trial · 2025: 1 paper, 1 trial · 2026: 3 papers

Papers 13

  1. NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. Co-author DOI 10.1038/s41467-026-68409-0↗
  2. Chemotherapy Reawakens Dormant Disseminated Pancreatic Cancer Cells in the Liver by Promoting Senescent Hepatocyte-Induced Neutrophil Extracellular Traps. Co-author DOI 10.1158/0008-5472.can-26-0151↗
  3. Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring. Co-author DOI 10.1158/2159-8290.cd-25-1627↗
  4. Safety and efficacy of intraoperative radiation therapy using a low-energy X-ray source for resectable pancreatic cancer: an interim evaluation of an ongoing p… Co-author DOI 10.20892/j.issn.2095-3941.2024.0287↗
  5. Bioinformatics analyses of infiltrating immune cell participation on pancreatic ductal adenocarcinoma progression and in vivo experiment of the therapeutic eff… Last author DOI 10.1016/j.jep.2023.117590↗
  6. Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022. First author DOI 10.1002/cai2.60↗
  7. Clinical Efficacy and Safety of Traditional Medicine Preparations Combined With Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analy… Co-author DOI 10.3389/fonc.2022.828450↗
  8. Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes. Co-author DOI 10.1002/cam4.3679↗
  9. Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma. Last author DOI 10.20892/j.issn.2095-3941.2020.0516↗
  10. A Network Pharmacology Approach to Determine the Mechanisms of Action of Shuangshen Granules in Suppressing Pancreatic Cancer Precursor Lesions Last author DOI 10.21203/rs.3.rs-132208/v1↗
  11. Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.47629↗
  12. Study on the treatment of pancreatic cancer with integrated traditional Chinese and Western medicine: A study protocol of a multicenter prospective cohort stud… First author DOI 10.1097/md.0000000000017975↗
  13. Using the Risk Factors of Pancreatic Cancer and Their Interactions in Cancer Screening: A Case-Control Study in Shanghai, China. Co-author DOI 10.5334/aogh.2463↗

Trials 2

  1. QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer Study chair NCT06951997↗
  2. AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC Study chair NCT06472037↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jihui Hao · 4 shared papers, 2025–2026 · strength 0.91
  2. Chuntao Gao · 3 shared papers, 2025–2026 · strength 0.71
  3. Baojin Hua · 4 shared papers, 2019–2024 · strength 0.52
  4. Juling Jiang · 4 shared papers, 2019–2024 · strength 0.52
  5. Tianxing Zhou · 2 shared papers, 2026 · strength 0.45
  6. Shangheng Shi · 2 shared papers, 2026 · strength 0.45
  7. Xing Zhang · 3 shared papers, 2019–2024 · strength 0.42
  8. Xiuchao Wang · 2 shared papers, 2026 · strength 0.40
  9. Song Gao · 2 shared papers, 2026 · strength 0.40
  10. Tiansuo Zhao · 2 shared papers, 2026 · strength 0.40
  11. Wenna Jiang · 2 shared papers, 2021–2026 · strength 0.37
  12. Jiaqi Hu · 2 shared papers, 2022–2024 · strength 0.33
  13. Xingyun Chen · 1 shared paper, 2025 · strength 0.27
  14. Yuxiao Liu · 1 shared paper, 2025 · strength 0.27
  15. Wei Wang · 1 shared paper, 2025 · strength 0.27
  16. Haorui Li · 1 shared paper, 2025 · strength 0.27
  17. Le Zhang · 1 shared paper, 2023 · strength 0.26
  18. Yi Ba · 1 shared paper, 2023 · strength 0.26
  19. Liangliang Wu · 1 shared paper, 2026 · strength 0.25
  20. Shengyu Yang · 1 shared paper, 2026 · strength 0.20
  21. Zhi Ji · 1 shared paper, 2026 · strength 0.20
  22. Chongbiao Huang · 1 shared paper, 2026 · strength 0.20
  23. Jun Yu · 1 shared paper, 2026 · strength 0.20
  24. Yongjie Xie · 1 shared paper, 2026 · strength 0.20
  25. Qingxiao Fang · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.